In the aftermath of the 2020 biotech surge and its subsequent contraction in 2022, the biotech industry has been characterized by significant volatility. There were 21 biotechnology IPOs in 2022, a notable decrease from the record-breaking 104 IPOs in 2021.

To review the highs and lows of 2023 and explore what lies ahead in 2024, distinguished biotech analyst and co-founder of Endpoints News John Carroll joins Hercules Capital’s Janice Bourque. Carroll brings 45 years of award-winning journalism, and a specialization in biopharma spanning over two decades to discuss the biggest pharma deals and surprises of 2023, the impact of AI on drug development, the future of biotech in Asia, and much more.

Topics Include:

• The biggest pharma deals and surprises of 2023
• AI’s impact on drug development
• Whether or not the Inflation Reduction Act will impact pricing
• John’s major lessons from 2023
• The future of biotech in Asia
• The greatest concerns for the biotech industry going into 2024
• John’s hopes for the industry in the new year
• And other topics…

John D. Carroll is a biotech analyst and writer with decades of prize-winning experience in journalism. A co-founder of Endpoints News, he has covered biopharma for the past 15 years. Carroll has been quoted by The New York Times, The New Yorker, Financial Times, The Times of London and more. He’s also keynoted at biotech gatherings around the world and addressed student audiences at MIT and Harvard. Carroll has contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press. He spent 6 years as editor and publisher of the Dallas Business Journal, was publisher of Texas Business and early in his career was part of a Pulitzer Prize-winning team of reporters and editors at the Kansas City Star & Times.

This podcast is produced by Hercules Capital, Inc. (“Hercules”) for informational purposes only. Views expressed are the speakers’ own as of the recording date and do not necessarily reflect those of Hercules or its affiliates. Nothing here is investment, legal, or tax advice, an offer or commitment to provide financing, or an offer of any security. Guests may be associated with current, former, or prospective Hercules portfolio companies. Their appearance is not an endorsement, and they are not compensated.